Not to be completely corny, but it’s true. Few nonprofits have dared to leverage venture philanthropy to creatively and proactively usher in new therapies like LLS has. And we have been doing it for years via our Therapy Acceleration Program (TAP), a strategic initiative to speed up blood cancer drug development and supportive diagnostics. Through TAP, we forge partnerships with universities and biotech companies, harnessing resources that can more rapidly transform promising research into critically needed therapies, including therapies that might otherwise go undeveloped.
Just last week, LLS awarded $1.68 million from TAP to Anand Jillella, M.D., of the Georgia Regents University in Augusta, GA. Dr. Jillella seeks to reduce the mortality rate of patients diagnosed with APL, a rare subtype of acute myeloid leukemia that affects marrow cells can promyelocytes, by educating community oncologists and hematologists and providing them with a tool to help direct care for newly diagnosed patients.
His tool of choice? A simple and straight-forward algorithm that can be used anywhere. So patients who don’t have access to or live far from an academic institution can still get the best of care at a crucial time in their cancer journey.
A simple solution to a very large obstacle for some of our patients. And just one example of how LLS is proactively making someday, today.
To learn more about how you can help create a world without blood cancer today, visit http://www.lls.org/somedayistoday.